Speakers

Expand/Collapse

Joel Weinstock
Chief, Division of Gastroenterology/Hepatology
Tufts University School of Medicine

Day One

Thursday 13th December 2018

1:15 pm | Exploring the Etiology of Inflammatory Bowel Disease

Andres Hurtado-Lorenzo
Senior Director of Translational Research
Crohn’s & Colitis Foundation

Dr. Andres Hurtado-Lorenzo is the Senior Director of Translational Research at the Crohn's and Colitis Foundation. He is responsible for planning and oversight the Foundation's translational research portfolio in the fields of Precision Medicine, Genetics, Microbiome, Fibrosis, and Venture Philanthropy to advance development of IBD therapeutics, diagnostics, devices and other products that can benefit patients. He is a translational scientist leader with proven success directing multidisciplinary teams in the biotech and pharmaceutical industry (Wyeth, Pfizer, Proteostasis Therapeutics), resulting in the development of candidate drugs currently tested in clinical trials. He obtained his Ph.D. in Molecular Medicine from the University of Manchester in the UK, where he pioneered work in viral gene therapy for neurodegenerative diseases. He completed his postdoctoral work at Harvard Medical School, Massachusetts General Hospital and Columbia University, where he conducted groundbreaking research on autophagy and other protein degradation pathways. His research has been published in books and high and impact journals like nature cell biology and nature communications.

Day One

Thursday 13th December 2018

8:30 am | Advancing Precision Medicine in IBD to Deliver Tailored Treatments

Meina Tang
Principal Scientist, Clinical Pharmacology
Genentech

Dr. Tang is a principal scientist and therapeutic area lead for autoimmune/inflammation diseases in the department of clinical pharmacology within the development science organization. Soon after joining Genentech in 2009, Dr. Tang was appointed as the pharmacology sub-team leader for two biologic programs and was the clinical pharmacology functional lead managing 8 development programs within inflammation and autoimmune disease areas.

Prior to joining Genentech, Dr. Tang was a Director of PK/PD at PDL Biopharma (previously named as “Protein Design Labs”). Overall, Dr. Tang has near 20 years of Biopharma/Biotech industry experience and was involved in the clinical development of 18 molecules, including monoclonal antibodies, F’ab fragment, Fusion protein and small molecule drugs, primarily in autoimmune or inflammatory disease areas including Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Lupus, Psoriasis and Asthma.

Day One

Thursday 13th December 2018

9:00 am | Designing Pediatric Studies Towards More Executable Trials for Pediatric IBD Patients

Rob Yang
Computational Biology Group Leader, I&I TCoE
Celgene

Rob Yang is a computational biologist with a broad experience in omics analyses and signal extractions from longitudinal studies with a special emphasis in neuroscience. Before joining Celgene Rob was Director, Computational Biology iMED Neuroscience at AstraZeneca after working at Pfizer from 2013-2016 following his Postdoc at Harvard Medical School.

Day One

Thursday 13th December 2018

1:45 pm | Pharmacogenomics in Ulcerative Colitis

Carolyn Cuff
Senior Director, Translational Immunology Department
AbbVie

Carolyn Cuff is Senior Director, Translational Immunology Department at AbbVie Bioresearch Center. Prior to this role, Carolyn was a Leader in Translational Immunology Discovery (2014-2018), Project Director (2012-2014), Associate Director of Pharmacology at Abbott Immunology (2011 – 2012) and Group Leader, Respiratory Pharmacology (2007-2011). Carolyn received her PhD in focused in Immunology/Pathology from Albert Einstein College of Medicine of Yeshiva University.

Day One

Thursday 13th December 2018

2:15 pm | Achieving Mucosal Healing as a Target for Therapeutic Efficacy in IBD

Arpita Maiti
Senior Director – External Science, Innovation,
Inflammation, Immunology & Microbiome
Pfizer

Day Two

Thursday 13th December 2018

8:30 am | Evaluating Early Stage Challenges & Opportunity for Partnerships in IBD

Mina Hassan-Zahraee
Director, Precision Medicine
Pfizer

Day One

Thursday 13th December 2018

10:45 am | Molecular Profiling of Ulcerative Colitis & Crohn's Patients

Alexis Scherl
Scientist, Research Pathologist
Genentech

Dr. Scherl is a board-certified anatomic pathologist with subspecialty training in gastrointestinal and liver pathology. Since joining Genentech in 2014, Dr. Scherl has supported the GastroImmunology pipeline, including hepatic research programs as well as clinical trials for etrolizumab and IL22-Fc. She has also participated in health authority interactions to enable the definition and implementation of novel histologic clinical trial endpoints for inflammatory bowel disease. Dr. Scherl completed her MD and PhD degrees through the Medical Scientist Training Program at Albert Einstein College of Medicine, followed by a residency in anatomic pathology at Weill-Cornell Medical Center and an ACGME-certified gastrointestinal/liver pathology fellowship at Yale University School of Medicine.

Day One

Thursday 13th December 2018

11:45 am | Implementing Histologic Endpoints in IBD Clinical Trials

Jessica Kenison-White
Scientist
AnTolRx

Day Two

Thursday 13th December 2018

9:30 am | Antigen-Specific Therapeutics for The Treatment of IBD

Ben Bradley
Head of Partnerships & Licensing
Chain Biotech

Ben has a first class BSc in Molecular Genetics in Biotechnology from Sussex University and an MSc in Applied Biosciences and Biotechnology from Imperial College (awarded top student). Ben also spent a year at GSK working in Bioinformatics. Prior to joining CHAIN Ben gained sales and business development skills working as a recruiter for top tier investment banks. Outside of science and business, Ben has been a successful personal trainer and swimming coach and continues to compete at masters’ swimming events.

Day Two

Thursday 13th December 2018

1:30 pm | Targeted Biotherapeutics for Ulcerative Colitis Using Engineered Anaerobic Bacteria

Assaf Oron
BiomX
Chief Business Officer

Assaf Oron has served as chief business officer since January 2017. Prior to this position, he served for over a decade at Evogene (NYSE:EVGN), an agriculture biotechnology company which utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity.  At Evogene, he worked in various roles such as executive vice president of corporate development and executive vice president of strategy and business development. From 2004 to 2006, Mr. Oron served as CEO of ChondroSite Ltd., a biotechnology company that develops engineered tissue products in the field of orthopedics. From 1999 to 2003, Mr. Oron was a senior project manager and strategic consultant at POC Ltd., a leading Israeli management consulting company. Mr. Oron holds an M.Sc. in Biology (bioinformatics) and a B.Sc. in Chemistry and Economics, both from Tel Aviv University.

Day Two

Thursday 13th December 2018

2:00 pm | Hitting Bacterial Targets for IBD With Phage Therapeutics

Peter Bunyard
Head of Immunology Biology
RedX Pharma

Dr. Peter Bunyard obtained his PhD in Immunology in 2002 from University College London and after post-doctoral research at Nottingham University has worked in auto-immune and fibrosis drug discovery. Peter’s career has progressed through a number of biotech and pharmaceutical companies including Celltech-UCB, GSK and Takeda. Currently Peter is head of fibrosis research at the UK biotech company Redx Pharma.

Day One

Thursday 13th December 2018

4:30 pm | GI-Targeted ROCK for Crohn’s Disease-Related Fibrosis

Diane Peters
Postdoctoral Fellow
John Hopkins Drug Discovery

Dr. Peters is a postdoctoral fellow with Johns Hopkins Drug Discovery in Baltimore, MD where she leads a research project aimed at developing small molecule therapeutics for inflammatory bowel disease. Dr. Peters received her PhD in Pharmacology from Tufts University in 2006 followed by a DVM and MS in laboratory animal medicine in 2008. Concurrent with her research efforts Dr. Peters is pursuing advanced veterinary specialty training in laboratory animal medicine at the Johns Hopkins School of Medicine.

Day One

Thursday 13th December 2018

4:00 pm | FOLH1/GCPII Inhibitors: Novel Small Molecule Therapeutics for the Treatment of IBD

Pernilla Sandwall
Chief Operating Officer
InDex Pharmaceuticals

Sandwall has worked at Merck & Co. Inc. (MSD) for more than 20 years, where she worked with clinical research at both the subsidiary in Sweden and at the head office in the USA. She has experience from previous positions as clinical trial leader and project manager, as well as from strategic work as head of clinical research. In recent years she has worked with global patient recruitment, strategies for the selection of trial centers and study implementation. She also has experience with the Change Management and Lean Six Sigma methodology. She holds a Pharmacy from Uppsala University.

Day One

Thursday 13th December 2018

11:15 am | Clinical Development of the TLR-9 Agonist Cobitolimod for Ulcerative Colitis Patients: A Late Stage Drug Candidate with a Novel Mode of Action

Jay Madan
Founder, President & Chief Business Officer
Innnovate Biopharmaceuticals

Mr. Madan founded Private Innovate in 2012 and began serving as its president and as a member of its board of directors at such time, and he became our president and a member of our board of directors in connection with the completion of the Merger. In March 2018, Mr. Madan was also appointed as our chief business officer and serves as our interim principal financial officer and interim principal accounting officer. Prior to founding Private Innovate, Mr. Madan was an independent contractor advising multiple life sciences companies, including Reliance Life Sciences, Millipore, Baxter, Dade Behring and Goodwin. This experience in working across multiple teams led him to develop a global network of healthcare professionals. From July 2007 to November 2008, Mr. Madan served as the vice president of business development at Reliance Biopharmaceuticals Pvt. Ltd., a part of Reliance Industries Ltd., India's largest conglomerate. While at Reliance and Goodwin, Mr. Madan was focused on the development of their contract manufacturing businesses. Mr. Madan holds a B.S. in chemical engineering from University of Mumbai and an M.S. in chemical engineering from Washington State University. We believe that Mr. Madan's role as a founder of lnnovate and extensive experience in the life sciences and biotech industries qualifies him to serve on our board of directors.

Day Two

Thursday 13th December 2018

2:30 pm | Insights Outside of IBD to Inform New Therapeutic Targets

Elran Haber
Chief Executive Officer
Biomica

Dr. Haber serves as Biomica’s Chief Executive Officer. Prior to joining Biomica Dr. Haber served as Therapix Biosciences (Nasdaq, TASE: TRPX) CEO leading the company to a successful IPO on Nasdaq, and advancing the Company's programs to clinical stage. Dr. Haber spent more than 10 years as Chairman and board member of several privately held, and publicly traded companies. Dr. Haber has served in senior executive roles in various life science companies and a private investment firm. Dr. Haber holds a PhD in Pharmaceutical Science and an MBA in Finance & Financial Engineering, both from The Hebrew University of Jerusalem, Israel

Day Two

Thursday 13th December 2018

12:00 pm | Microbiome Functional Genomics Reveals Novel Bacterial Strains for Reduction of Inflammation in Crohn’s Disease

Hella Kohlhof
Chief Scientific Officer
Immunic Therapeutics

Dr. Hella Kohlhof is the CSO of Immunic AG and Managing Director of Immunic’s research subsidiary, Immunic Research GmbH, Halle (Saale). She joined Immunic in January 2017 from 4SC AG, a publicly listed German biotech company where she was responsible for the management of the clinical product portfolio. Hella Kohlhof studied biology in Aachen, Gothenburg (Sweden) and Munich and received her Doctorate in Biology from the Ludwig Maximilians University of Munich (Germany). During her Ph.D. and PostDoc position at the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Centre in Munich, she worked on normal and malignant B cell development influenced by Notch and Epstein Barr Virus mediated signaling. In 2008, she joined 4SC AG as a research scientist and group leader and established the research laboratory for translational pharmacology. She worked on 4SC’s preclinical and clinical stage projects in the oncology and immunology field, including IMU-838 and IMU-935. From 2011 on, Hella was responsible for the management and development of 4SC’s epigenetic clinical stage small molecule inhibitor 4SC-202. In early 2015, as Director Development Projects, she took over responsibility for the complete development portfolio of 4SC AG. Hella has a very strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational pharmacology, clinical trial design and biomarker development.

Day One

Thursday 13th December 2018

3:30 pm | IMU-838 in Clinical Phase 2 - New Selective Oral Treatment for IBD

Alan Moss
Associate Professor of Medicine at Harvard Medical School
Beth Israel Deaconess Medical Center

Alan Moss, MD, leads a translational research group in the Division. The lab's current interests are in fecal biomarkers, vitamin D as an immunomodulator, and the microbiome as a therapeutic target. These studies are funded by NIDDK and foundation grants. We have published extensively on the phenotype of mucosal T-cells, serum markers of intestinal inflammation, and exosome biomarkers. Our clinical publications include meta-analyses, prognosis in Ulcerative Colitis, and medication adherence.

Day Two

Thursday 13th December 2018

11:00 am | Positioning Microbial Therapies in the IBD Treatment Algorithim

Khahayarsha Khazaie
Professor of Immunology
Mayo Clinic

Khashayarsha Khazaie, Ph.D., D.Sc., directs basic and translational research in cancer immunology and immunosenescence. Dr. Khazaie’s lab studies immune responses that help tumors grow and spread as well as immune responses that protect against cancer. A major focus is on regulatory T cells (Tregs), their subsets, and their diverse functions in regulating inflammation and immunity in the gastrointestinal tract. In this context, there is interest in the role of microbiota and circadian rhythm.

Day Two

Thursday 13th December 2018

3:30 pm | Treg Diversity & Function in Colon Cancer

Jason Ridlon
Assistant Professor
University of Illinois at Urbana Campaign

Jason M. Ridlon joined the faculty at the University of Illinois at Urbana-Champaign in 2015 and is an assistant professor with appointments in the Department of Animal Sciences, the Division of Nutritional Sciences and the Carl R. Woese Institute for Genomic Biology. Dr. Ridlon obtained his Ph.D. in anaerobic bacteriology from Virginia Commonwealth University School of Medicine in 2008 and remained as a postdoctoral fellow in the Departments of Microbiology & Immunology and Internal Medicine, Division of Gastroenterology and Hepatology until 2012. He then became and Affiliate Assistant Professor in the Department of Microbiology & Immunology (2012-Present) and a research microbiologist at the Department of Veterans Affairs in Richmond, VA, from 2012-2015. Research in his laboratory focuses on the human gut “sterolbiome”, the collective genes involved in biotransformation of bile acids, glucocorticoids, and pharmaceutical steroids. His laboratory studies sterolbiome genes and enzymes in several model systems including germ-free mice and chickens, mini-bioreactors, and human clinical samples. We utilize transcriptomics, metagenomics, enzymology and structural biology to study the sterolbiome at multiple levels. Our goal is to modulate the steroid and bile acid metabolome and generate specific inhibitors of sterolbiome targets to accomplish this, with the long-term goal of treating human disease and improving animal production. Dr. Ridlon has authored 34 peer reviewed research articles and reviews. His 2006 review on bile salt metabolism by human intestinal bacteria has been cited 1195 times. Among research articles is the utilization of RNA-Seq to identify a novel side-chain cleavage pathway responsible for converting cortisol into 11-oxy-androgens. He has discovered and characterized several bacterial enzymes responsible for formation of cancer-promoting secondary bile acids.

Day Two

Thursday 13th December 2018

5:00 pm | The Microbiology & Biochemistry of Cancer-Promoting Secondary Bile Acid Production

Christine McDonald
Associate Staff, Lerner Research Institute
Cleveland Clinic

Day Two

Thursday 13th December 2018

10:00 am | The Immune System & the Microbiome: Drivers of IBD Pathogenesis & Opportunities for IBD Therapeutics

Rex Gaskins
Professor
University of Illinois at Urbana Campaign

Rex Gaskins joined the faculty at the University of Illinois at Urbana-Champaign in 1992 and is a professor with appointments in the Departments of Animal Sciences and Pathobiology, the Division of Nutritional Sciences and the Carl R. Woese Institute for Genomic Biology. He obtained the Ph.D. degree in cell biology from The University of Georgia in 1989. From 1989-92, he completed postdoctoral studies in immunology and genetics at The Jackson Laboratory in Bar Harbor, Maine. Research in his laboratory focuses on host-intestinal microbe interactions relevant to colorectal cancer with a particular interest in microbial sulfur and hydrogen metabolism. Efforts to understand colonic mucosal responses to hydrogen sulfide led to further interest in redox regulation of tumorigenesis resulting in a long-time collaboration with bioengineering faculty at Illinois to create genetically-encoded biosensors and engineered platforms for the study of redox poise in subcellular compartments in live cells. Professor Gaskins has authored 156 peer-reviewed publications and book chapters and has won numerous awards including a Future Leaders Award from the International Life Sciences Institute, the Bio-Serv Award from the American Society of Nutrition, a Burroughs Wellcome Fund visiting scientist fellowship (University of Reading), and a Sir Frederick McMaster CSIRO Research Fellowship (University of Queensland). From 1999-2002, he was named a University Scholar at Illinois, the highest honor bestowed by fellow faculty, received in 2012 the Paul A. Funk Award from Illinois, and in 2016 received the Distinguished Scientist Award from the Society for Experimental Biology and Medicine. Professor Gaskins serves as Deputy Director of the NIH-supported Tissue Microenvironment Training Program and as Associate Director for Education of the Cancer Center at Illinois.

Day Two

Thursday 13th December 2018

4:30 pm | Microbial Sulfur Metabolism & Colorectal Cancer Risk

Fotini Gounarf
Associate Professor
The University of Chicago

Dr. Fotini Gounari Ph.D. is a molecular immunologist  and an expert in thymic development and mucosal immunity. She started her career in epigenetic regulation of gene expression and has continued to apply her expertise to T-cell biology in health and disease. She trained at the National Institute for Medical Research in London with Dr. Robin Holliday, and at the European Molecular Biology in Heidelberg Germany.  She served as junior faculty Dana Farber Institute at Harvard Medical School and she is currently an Associate Professor of Medicine at University of Chicago. Her areas of research are T-cell/regulatory T-cell development and function. Her studies focus on the Wnt/b-catenin signaling in T-lymphocytes and the interface of this pathway with gut microbiota and their metabolites.  Dr. Gounari aims to identify key molecular pathways that are deregulated in chronic inflammation and cancer. Identification of such pathways will elucidate the molecular etiology of autoimmune diseases and cancer, and holds the promise to lead to effective immune therapies.

Day Two

Thursday 13th December 2018

4:00 pm | B-catenin Promotes Colitis & Colon Cancer Through Imprinting of Pre-Inflammatory Properties in Tregs

Adam Cheifetz
Director, Center of Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center

Day Two

Thursday 13th December 2018

9:00 am | Role of Therapeutic Drug Monitoring in IBD

Jennifer Russo Wortman
Vice President Clinical Discovery & Research Technologies
Seres Therapeutics

Jennifer Russo Wortman is the Vice President, Clinical Discovery and Research Technology at Seres Therapeutics. She is responsible for scientific leadership across Seres drug discovery platform and oversight of research technologies including assay development, -omics data generation, analysis infrastructure and  methods development. Prior to joining Seres Therapeutics, Jennifer was the Director of Microbial Informatics at the Broad Institute, responsible for the computational infrastructure and analytical strategies supporting the Genome Center for Infectious Diseases (GCID). That followed three years as Associate Director of Bioinformatics at the Institute for Genome Sciences (IGS) at the University of Maryland School of Medicine, where she was the co-Principal Investigator of the Human Microbiome Project's Data Analysis and Coordination Center (HMP DACC). She has over 75 peer reviewed publications and has made significant contributions to the published genome analyses of fruit fly, human, mouse, and mosquito as well as diverse pathogenic fungi, parasites and bacteria.

Day Two

Thursday 13th December 2018

11:30 am | Developing Microbiome Therapeutics for Ulcerative Colitis